STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non–Small-Cell Lung Cancer
JCO Precision Oncology · 2023
DOI: 10.1200/po.22.00273 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Rohan R Katipally und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Cellular Oncology, University of Chicago Medicine, Chicago, IL. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Molecular factors predicting relapse in early-stage non–small-cell lung cancer (ES-NSCLC) are poorly understood, especially in inoperable patients receiving radiotherapy (RT). In this study, we compared the genomic profiles of inoperable and operable ES-NSCLC. MATERIALS AND METHODS This retrospective study included 53 patients with nonsquamous ES-NSCLC (stage I-II) treated at a single institution (University of Chicago) with surgery (ie, operable; n = 30) or RT (ie, inoperable; n = 23) who underwent tumor genomic profiling. A second cohort of ES-NSCLC treated with RT (Stanford, n = 39) was included to power clinical analyses. Prognostic gene alterations were identified and correlated with clinical variables. The primary clinical end point was the correlation of prognostic genes with the cumulative incidence of relapse, disease-free survival, and overall survival (OS) in a pooled RT cohort from the two institutions (N = 62). RESULTS Although the surgery cohort exhibited lower rates of relapse, the RT cohort was highly enriched for somatic STK11 mutations (43% v 6.7%). Receiving supplemental oxygen (odds ratio [OR] = 5.5), 20+ pack-years of tobacco smoking (OR = 6.1), and Black race (OR = 4.3) were associated with increased frequency of STK11 mutations. In the pooled RT cohort (N = 62), STK11 mutation was strongly associated with inferior oncologic outcomes: 2-year incidence of relapse was 62% versus 20% and 2-year OS was 52% versus 85%, remaining independently prognostic on multivariable analyses (relapse: subdistribution hazard ratio = 4.0, P = .0041; disease-free survival: hazard ratio, 6.8, P = .0002; OS: hazard ratio, 6.0, P = .022). STK11 mutations were predominantly associated with distant failure, rather than local. CONCLUSION In this cohort of ES-NSCLC, STK11 inactivation was associated with poor oncologic outcomes after RT and demonstrated a novel association with clinical hypoxia, which may underlie its correlation with medical inoperability. Further validation in larger cohorts and investigation of effective adjuvant systemic therapies may be warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation and Cellular Oncology, University of Chicago Medicine, Chicago, IL.
- The Pritzker School of Medicine, The University of Chicago, Chicago, IL.
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA.
- Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL.
- Section of Hematology/Oncology, Department of Medicine, NorthShore University HealthSystem, Evanston, IL.
- Department of Pathology, University of Chicago Medicine, Chicago, IL.
ORCID-Profile: Rohan R Katipally, Michael S Binkley, Alice L Jiang, Sherin J Rouhani, Victor Ng, Christine M Bestvina, Everett E Vokes, Mark K Ferguson, Maximilian Diehn, Sean P Pitroda
Förderung
- NCI NIH HHS
Zitieren
APA
Katipally, R. R., Spurr, L. F., Gutiontov, S. I., Turchan, W. T., Connell, P., Juloori, A., Malik, R., Binkley, M. S., Jiang, A. L., Rouhani, S. J., Chervin, C. S., Wanjari, P., Segal, J. P., Ng, V., Loo, B. W., Gomez, D. R., Bestvina, C. M., Vokes, E. E., Ferguson, M. K., …, & Pitroda, S. P. (2023). STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non–Small-Cell Lung Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.22.00273
Vancouver
Katipally RR, Spurr LF, Gutiontov SI, Turchan WT, Connell P, Juloori A, et al. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non–Small-Cell Lung Cancer. JCO Precision Oncology. 2023. doi:10.1200/po.22.00273
BibTeX
@article{Katipally2023,
author = {Katipally, Rohan R and Spurr, Liam F and Gutiontov, Stanley I and Turchan, William Tyler and Connell, Philip and Juloori, Aditya and Malik, Renuka and Binkley, Michael S and Jiang, Alice L and Rouhani, Sherin J and Chervin, Carolina Soto and Wanjari, Pankhuri and Segal, Jeremy P and Ng, Victor and Loo, Billy W and Gomez, Daniel R and Bestvina, Christine M and Vokes, Everett E and Ferguson, Mark K and Donington, Jessica S and Diehn, Maximilian and Pitroda, Sean P},
title = {STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non–Small-Cell Lung Cancer},
journal = {JCO Precision Oncology},
year = {2023},
doi = {10.1200/po.22.00273}
}
EUVIMED